Proteomics in Chronic Arthritis—Will We Finally Have Useful Biomarkers?
Purpose of Review
Current technical advances enable the assessment of the complex changes in body fluid proteomes and thus allow for the discovery of biomarker signatures rather than just following differences of a single marker. In this review, we aim to summarize current approaches to discover and evaluate multi-biomarker panels for improved monitoring of chronic arthritis disease activity.
Mass spectrometry and affinity proteomic methodologies have been used to identify biomarker panels in synovial fluid, serum, plasma, or urine of pediatric and adult chronic arthritis patients. Notably, despite the numerous efforts to develop new and better biomarker panels, very few have undergone extensive analytical and clinical validation and been adopted into routine use for patient benefit.
There remains a significant gap between discovery of chronic arthritis biomarker signatures and their validation for clinical use.
KeywordsProteomics Biomarkers Proteins Peptides Disease activity Discovery Validation
Compliance with Ethical Standards
Conflict of Interest
DF declares the receipt of research grant support and honoraria from Pfizer, Novartis, Sobi, and Chugai-Roche. The UCD Conway Institute and Proteomics Core is funded by the Programme for Research in Third level Institutions, as administered by Higher Education Authority of Ireland. Research in SRP’s lab is supported by grants from the Health Research Board, Enterprise Ireland and Science Foundation Ireland and previously including the EU funded FP7 MIAMI project. Dr. Pennington reports role as Founder and CSO of Atturos (www.atturos.com) which is developing prostate cancer multiplexed protein biomarker test on MRM platform. Drs. Kessel and Foell have a patent “means and methods for diagnosing and treating inflammatory disorders” (WO 2016/178154 A1) issued to Muenster University. Dr. Foell has a patent “means and methods for diagnosing and treating inflammatory disorders” (WO 2016/178154 A1) issued to Muenster University. Angela McArdle, Emely Verweyen, Toni Weinhage, and Helmut Wittkowski declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 9.Sandberg S, Fraser CG, Horvath AR, Jansen R, Jones G, Oosterhuis W, et al. Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med. 2015;53(6):833–5.CrossRefPubMedGoogle Scholar
- 18.• Rodero MP, Decalf J, Bondet V, Hunt D, Rice GI, Werneke S, et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J Exp Med. 2017;214(5):1547–55. First published application of digital ELISA for quantification of interferon α. CrossRefPubMedPubMedCentralGoogle Scholar
- 32.• Too CL, Murad S, Hansson M, Alm LM, Dhaliwal JS, Holmdahl R, et al. Differences in the spectrum of anti-citrullinated protein antibody fine specificities between Malaysian and Swedish patients with rheumatoid arthritis: implications for disease pathogenesis. Arthritis Rheumatol. 2017;69(1):58–69. Peptide array identifying disease-related antibody profiles. CrossRefPubMedGoogle Scholar
- 34.Ramirez J, Inciarte-Mundo J, Cuervo A, Ruiz-Esquide V, Hernandez MV, Sanmarti R, et al. Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission. Clin Exp Rheumatol. 2017;35(1):74–9.PubMedGoogle Scholar
- 36.Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, Katselis G, et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum. 2012;64(6):1828–37.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Smolenska Z, Smolenski RT, Zdrojewski Z. Plasma concentrations of amino acid and nicotinamide metabolites in rheumatoid arthritis—potential biomarkers of disease activity and drug treatment. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2016;21(3):218–24.CrossRefGoogle Scholar
- 45.•• Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, et al. Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2017;76(1):166–72. Important multiplexed biomarker profiling in pediatric rheumatology CrossRefPubMedGoogle Scholar
- 51.Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959–64.CrossRefPubMedGoogle Scholar
- 54.de Jager W, Prakken BJ, Bijlsma JW, Kuis W, Rijkers GT. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods 2005;300(1–2):124–135.Google Scholar
- 59.•• Hambardzumyan K, Saevarsdottir S, Forslind K, Petersson IF, Wallman JK, Ernestam S, et al. A multi-biomarker disease activity score and the choice of second-line therapy in early rheumatoid arthritis after methotrexate failure. Arthritis Rheumatol. 2017;69(5):953–63. Use of MBDA for therapeutic decision-making in RA. CrossRefPubMedPubMedCentralGoogle Scholar
- 64.Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkotter C, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000;43(3):628–37.CrossRefPubMedGoogle Scholar
- 65.Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 2008;58(12):3924–31.CrossRefPubMedPubMedCentralGoogle Scholar
- 66.Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, Wulffraat N, Wedderburn L, Stanevicha V, Mihaylova D, Harjacek M, Len C, Toppino C, Masi M, Minden K, Saurenmann T, Uziel Y, Vesely R, Apaz MT, Kuester RM, Elorduy MJR, Burgos-Vargas R, Ioseliani M, Magni-Manzoni S, Unsal E, Anton J, Balogh Z, Hagelberg S, Mazur-Zielinska H, Tauber T, Martini A, Foell D, for the Paediatric Rheumatology International Trials Organization (PRINTO) Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis 2012;71(12):1991–1997.Google Scholar
- 67.Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71(6):974–80.CrossRefPubMedGoogle Scholar
- 71.Holzinger D, Kessel C, Fall N, Grom A, de jager W, Vastert S et al. S100A12 as diagnostic tool in the differential diagnosis of SJIA associated MAS vs. primary or acquired HLH. Pediatric Rheumatology 2016(Supplement 1):P297.Google Scholar
- 73.Hirata S, Li W, Defranoux N, Cavet G, Bolce R, Yamaoka K, et al. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: a retrospective observational study. Mod Rheumatol. 2015;25(3):344–9.Google Scholar
- 74.Lee YC, Hackett J, Frits M, Iannaccone CK, Shadick NA, Weinblatt ME, et al. Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia. Rheumatology (Oxford). 2016;55(4):640–8.CrossRefGoogle Scholar